Meg Rivers

Meg Rivers is a senior editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Articles

What’s Next for COVID-19 Vaccines and Variants?

Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants.

Ensuring Quality When Sourcing Biopharmaceutical Raw Materials

Defining expectations, such as GMPs, is paramount for sourcing the right biopharmaceutical raw materials.

Serialization on a Global Scale: Deep Dive into the US DSCSA and EU FMD – Regulatory | Part 4

Global supply chain experts examine implications of the DSCSA as well as topical considerations around the EU's FMD in this serialization video series ft. manufacturing, packaging, software, and regulatory experts.

Serialization on a Global Scale: Deep Dive into the US DSCSA and EU FMD – Software and Data Management | Part 3

Global supply chain experts examine implications of the DSCSA as well as topical considerations around the EU's FMD in this serialization video series ft. manufacturing, packaging, software, and regulatory experts.

Serialization on a Global Scale: Deep Dive into the US DSCSA and EU FMD – Packaging | Part 2

Global supply chain experts examine implications of the DSCSA as well as topical considerations around the EU's FMD in this serialization video series ft. manufacturing, packaging, software, and regulatory experts.

Serialization on a Global Scale: Deep Dive into the US DSCSA and EU FMD – Manufacturing | Part 1

Global supply chain experts examine implications of the DSCSA as well as topical considerations around the EU's FMD in this serialization video series ft. manufacturing, packaging, software, and regulatory experts.

Visual Inspection: Seeing Room for Improvement?

Automatic visual inspection machines and artificial intelligence highlight inspection deficits for parenteral containers and units.

Serialization and Aggregation from a Manufacturing Perspective

For some manufacturers, the goal was to be fully compliant with the DSCSA, including both serialization and aggregation, from day one.

The Real Danger of Substandard and Counterfeit COVID-19 Vaccines

Low- and middle-income countries are at the greatest risk of receiving substandard and falsified COVID-19 vaccines.

In Vitro Pulls Ahead of In Vivo for Adventitious Agent Testing

Scientific advances open the way to alternatives to animal testing and in-vivo assays.